ERBB2 and breast carcinoma: The overexpression/amplification of human erb-b2 receptor tyrosine kinase 2 (ERBB2 or HER2), a member of the epidermal growth factor receptor family, is observed in 15–20% of breast cancers and is predictive in the treatment response of its targeted therapeutic agents [2–4].